Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic than current therapies due to the agents selective growth and amplification in tumor cells. To date, these agents have been highly safe in patients but have generally fallen short of their expected therapeutic value as monotherapies. Consequently, new approaches to generating highly potent oncolytic viruses are needed. To address this need, we developed a new method that we term "Directed Evolution" for creating highly potent oncolytic viruses. METHODOLOGY/PRINCIPAL FINDINGS: Taking the "Directed Evolution" approach, viral diversity was increased by pooling an array of serotypes, then passaging the pools under conditions that invite recombination between serotypes. These highly diverse viral pools were then placed under stringent directed selection to generate and identify highly potent agents. ColoAd1, a complex Ad3/Ad11p chimeric virus, was the initial oncolytic virus derived by this novel methodology. ColoAd1, the first described non-Ad5-based oncolytic Ad, is 2-3 logs more potent and selective than the parent serotypes or the most clinically advanced oncolytic Ad, ONYX-015, in vitro. ColoAd1's efficacy was further tested in vivo in a colon cancer liver metastasis xenograft model following intravenous injection and its ex vivo selectivity was demonstrated on surgically-derived human colorectal tumor tissues. Lastly, we demonstrated the ability to arm ColoAd1 with an exogenous gene establishing the potential to impact the treatment of cancer on multiple levels from a single agent. CONCLUSIONS/SIGNIFICANCE: Using the "Directed Evolution" methodology, we have generated ColoAd1, a novel chimeric oncolytic virus. In vitro, this virus demonstrated a >2 log increase in both potency and selectivity when compared to ONYX-015 on colon cancer cells. These results were further supported by in vivo and ex vivo studies. Furthermore, these results have validated this methodology as a new general approach for deriving clinically-relevant, highly potent anti-cancer virotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101 · cited 1×
“Early clinical trials and pre-clinical studies have demonstrated synergy of this type of novel cancer therapy with standard of care chemotherapy [5] and radiation [6,7,8].”
BackgroundCD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 792 · cited 8×
“Strong CD46 IHC staining was consistently seen in colon cancer tissue, but was absent or generally weak in normal colon and liver tissue.”
BackgroundSelf-citationRoelvink, P. W., Lizonova, A., Lee, J. G. M., Li, Y., Bergelson, J. M., Finberg, R. W., Brough, D. E., Kovesdi, I., & Wickham, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.7909-7915.1998 · Cited by 654
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., & Mehtali, M. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4805-4810.1996 · Cited by 653 · cited 1×
“The replication defective ColoAd1 (bp 461– 3397 deleted so as to eliminate the E1A and E1B genes) was derived by homologous recombination of ColoAd1 into a pBRderived plasmid in BJ5183 bacteria using methods as previously described [56].”
MethodSelf-citationRecent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536 · cited 1×
“Oncolytic viruses are unique anti-cancer agents capable of amplifying the input dose through replication in a tumor-dependent fashion. Human adenovirus (Ad) is one of a series of viruses being developed as oncolytic agents to treat human malignancies”
BackgroundChina Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489 · cited 3×
“To test whether ColoAd1 was selective for tumor cells over normal cells and thus, by definition, an oncolytic virus, ColoAd1 was examined in two different colon tumor cell lines (HT-29, DLD-1), and on primary endothelial and epithelial cells (HUVEC, HMEC) comparing its potency in each MTS assay to Ad5 and ONYX-015/H10…”
BackgroundInfluentialPackaging capacity and stability of human adenovirus type 5 vectors
Bett, A. J., Prevec, L., & Graham, F. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.5911-5921.1993 · Cited by 472 · cited 1×
“insertion sites [27] Given that the viral genome coding capacity of the human Ad is constrained [28] a consensus splice acceptor site”
BackgroundFishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 400 · cited 1×
“In contrast, tumor cell surface expression of CD46, the putative ColoAd1 receptor, appears to increase with stage and grade in a variety of cancers [48].”
BackgroundAdenovirus Type 11 Uses CD46 as a Cellular Receptor
Segerman, A., Atkinson, J. P., Marttila, M., Dennerquist, V., Wadell, G., & Arnberg, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9183-9191.2003 · Cited by 358 · cited 8×
“Strong CD46 IHC staining was consistently seen in colon cancer tissue, but was absent or generally weak in normal colon and liver tissue.”
BackgroundInfluentialImaging Transgene Expression with Radionuclide Imaging Technologies
Gambhir, S. S., Herschman, H. R., Cherry, S. R., Barrio, J. R., Satyamurthy, N., Toyokuni, T., Phelps, M. E., Larson, S. M., Balatoni, J., Finn, R., et al. (2000) · Neoplasia · doi:10.1038/sj.neo.7900083 · Cited by 358 · cited 1×
“HSV-1 TK, human thyroidal sodium iodide symporter,[51,52] ) and soluble marker peptides readily detectable in the bloodstream or via urine sampling (e.”
Background
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Oncolytic viruses for cancer immunotherapy
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00922-1 · Cited by 351
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Zheng, M., Huang, J., Tong, A., & Yang, H. (2019) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2019.10.007 · Cited by 295
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Metadata
- Authors
- Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., Seymour, L., Rubanyi, G. M., Harkins, R. N., & Hermiston, T. W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-06-18
- Volume
- 3
- Issue
- 6
- Pages
- e2409
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2013818959
- Cited by
- 200
- References
- 48
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.